drugset / Trial / NCT01110668

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

NCT01110668

Phase 2 Completed 2 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.

Timeline

Start
2008-09
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Nilotinib Small molecule